Two promising bridging therapies for overuse headaches

The Department of Health affects 1% to 2% of the general population. It is a burden on patients and the medical system.

Louis Ochoa

June 08, 2022 | | reading time: 3 minutes

Using too many pain relievers can cause a condition known as medication overuse headache. Photo: shutterstock.

between the headache patients For a longer period of overuse of MOH medications, response to treatment was lower, This highlights the importance of early diagnosis and prompt treatment of these headaches.

There is no consensus about the management of SESAL. Some centers rely on bridging therapy to relieve symptoms during withdrawal before starting preventive treatment.

Previous research on bridging therapy has yielded inconsistent results. Additional research and a better understanding of How a patient’s risk factors may affect response to treatment.

The study used medical records of hospitalized patients Third Pain Center Sina Hospital in Iran from March 2009 to June 2020. Among the inclusion criteria for the study is the presence of Between 18 and 60 years old Older adults with at least one outpatient treatment failure.

The Ministry of Health is defined by the International Classification of Headache Disorders-3. This definition defines Use of medications for severe symptoms or headaches For more than 15 days per month for at least 3 months.

Response to treatment was defined as an improvement of >50% in intensity or longer duration 72 hours after treatment. The response is rated = 50%.

The study included a total of 178 patients with the Ministry of Health. The mean age of patients was 43.29 years, and the majority of patients (82.5%) were Women and average duration Headache 17.05 ± 11.83 years and average duration from MOH it was 2.67 ± 3.78 years.

For the majority of patients (79.2%) the response rate was >50%. 37 patients (20.8%), the response rate was less than 50%. 94 patients treated with methylprednisolone and 70% of patients treated with celecoxib had a response rate >50%.

Aharon Interventions have now shown this significant response correlationIncluding IV valproate, GON block, intravenous (IV) magnesium therapy, indomethacin, or high-dose oral naproxen.

The study used a retrospective design for data collection and lacked the control group, which may have introduced bias. Additional variables, including specific biomarkers or genetic factors, were not considered in the study and may be related to treatment response.

Source consult here.